NCT Investigator-Initiated Trial (IIT) Program
The main mission of the NCT is to conduct innovative clinical-translational and internationally competitive research aimed at significantly improving the treatment outcomes and quality of life of cancer patients. The focus is on translating promising preclinical research results into scientifically sound multicenter clinical trials in the field of personalized oncology. This is done according to a structured clinical translation process.
In order to accomplish this task and to fill the NCT-sponsored trial portfolio, the NCT, together with its partners, is now initiating the continuous submission of study synopses.
Principal Investigators from all NCT parental institutions can submit study ideas at any time, which will be selected for funding or support in an evaluation process. The selection process is a continuous process and consists of several steps. An initial evaluation by an international panel of experts (NCT Trial Selection Board) is planned for Q4 of 2023. Thereafter, study ideas will be evaluated continuously on a quarterly basis.
Trials can be funded from the start of institutional funding in January 2024. In this way, a comprehensive portfolio of innovative studies will be gradually built up, which will either be funded by the NCT (Overarching Clinical Translational Trial (OCT2) program) or supported by the NCT through the provision of infrastructure (e.g. CTCs).